ATORX Stock Overview
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden.
Alligator Bioscience AB (publ) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr1.44|
|52 Week High||kr3.59|
|52 Week Low||kr1.30|
|1 Month Change||-19.05%|
|3 Month Change||-4.65%|
|1 Year Change||-57.77%|
|3 Year Change||-88.21%|
|5 Year Change||-95.01%|
|Change since IPO||-96.23%|
Recent News & Updates
Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|ATORX||SE Biotechs||SE Market|
Return vs Industry: ATORX underperformed the Swedish Biotechs industry which returned -28.8% over the past year.
Return vs Market: ATORX underperformed the Swedish Market which returned -24.4% over the past year.
|ATORX Average Weekly Movement||7.3%|
|Biotechs Industry Average Movement||8.5%|
|Market Average Movement||7.0%|
|10% most volatile stocks in SE Market||11.5%|
|10% least volatile stocks in SE Market||4.3%|
Stable Share Price: ATORX is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ATORX's weekly volatility (7%) has been stable over the past year.
About the Company
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells.
Alligator Bioscience AB (publ) Fundamentals Summary
|ATORX fundamental statistics|
Is ATORX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ATORX income statement (TTM)|
|Cost of Revenue||kr110.25m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Oct 20, 2022
|Earnings per share (EPS)||-0.74|
|Net Profit Margin||-828.86%|
How did ATORX perform over the long term?See historical performance and comparison